Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 47 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/26/2007


1.		Phase III Chemohormonal Therapy with ADR/CCNU/VCR/FXM vs CTX/MPA plus Immunotherapy with C. parvum for Metastatic Renal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				20 to 70								MSHMC-REN-2

Last Modified: 1/25/2008 First Published: 3/1/1997


2.		Phase III Randomized Study of Medroxyprogesterone Acetate Versus Observation for Prevention of Endometrial Pathology in Postmenopausal Women With Breast Cancer Treated With Adjuvant Tamoxifen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention, Treatment				Closed				18 and over				NCI				SWOG-S9630 CALGB-49901, SWOG-9630, S9630, NCT00002920


3.		CACP/HMM vs CACP/HMM/MPA for Advanced Epithelial Ovarian Tumor - A Phase III Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				no age specified								NCI-D79-019-073 BUCRC-751

Last Modified: 3/19/2008 First Published: 11/1/2001


4.		Phase III Randomized Study of Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women With a History of Node-Negative Invasive Carcinoma or Ductal Carcinoma in Situ of the Breast Who are Receiving Adjuvant Tamoxifen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 and over				NCI				E-2193 NCI-P01-0194, NCT00026286, ECOG-E2193

Last Modified: 11/30/2006 First Published: 2/1/2002


5.		Phase III Randomized Study of Medroxyprogesterone Versus Venlafaxine in Women With Symptomatic Hot Flashes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 and over				NCI				NCCTG-N99C7 NCI-P02-0204, NCT00030914


6.		Phase III Percutaneous Transfemoral Renal Artery Occlusion, Nephrectomy and Hormonal Therapy with Medroxyprogesterone Acetate for Metastatic Renal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				no age specified								MDA-U/u17

Last Modified: 11/1/1995


7.		Phase III Provera (MPA) vs ADR vs ADR/CTX for Stage III/IV or Recurrent Endometrial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				no age specified				NCI				GOG-48 GOG-7941, GOG-48


8.		Phase III Postinfarction Nephrectomy plus Medroxyprogesterone Acetate for Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				no age specified				NCI				SWOG-7956


9.		Phase III Comparison of Immuneron vs Depo-Provera in Patients with Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75								BGSM-89285 NCI-V85-0243

Last Modified: 8/1/1989


10.		Phase III Randomized Trial of Adjuvant Therapy with Medroxyprogesterone Acetate in Patients with High-Risk Endometrial Cancer (Summary Last Modified 08/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				any age								COSA-UK-NZ-E1/82

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute